US Biotech Sector Nears Commercialization Inflection Point on Key FDA ApprovalsGlobal Report·2 minutes agoCRSP+1.75%GENB-3.95%
Market Schizophrenia: The AI Gold Rush vs. The T-Bill Panic RoomGlobal Report·1 day ago, 04:13 AMBRO+5.67%ABNB+4.26%
The Biotech Survival Charade: Stop Buying the "AI Pivot" HypeGlobal Report·Jul 26 at 04:14 AMINM+1.83%ONCY-1.00%
Inside the Biotech Sector's Recent Clinical Catalyst WaveGlobal Report·Jul 25 at 04:17 AMGENB-3.95%IBRX-0.29%
Mid-to-Small Cap Growth Faces Earnings Test, Plus Twilio and SiTime's Latest MovesGlobal Report·Jul 25 at 04:13 AMTWLO-7.00%SITM-6.04%
The 2026 Biotech Divide: When Generative Biology Meets the FDA WallGlobal Report·Jul 24 at 04:13 AMINM+1.83%TXG+2.46%
Tech Pivots to Cloud Mega-Deals as AI Momentum Spills Into BiopharmaGlobal Report·Jul 22 at 04:17 AMAKAM-0.94%GENB-3.95%
Deconstructing the Value Chain of the Long Tail: From Physical Scarcity to Niche AggregationGlobal Report·Jul 21 at 04:13 AMNXE-1.50%METC-4.13%
The Great Biotech Reckoning: When AI and Gene Editing Meet Wall Street's Patience in 2026Global Report·Jul 19 at 04:13 AMAMGN+4.48%CRSP+1.75%
M&A, AI Drug Discovery, and Late-Stage Clinical Readouts Define US Biotech Q2 TrajectoryGlobal Report·Jul 18 at 04:13 AMAMGN+4.48%CRSP+1.75%
Nike, Shutterstock And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Sessionbenzinga_article·Jul 1 at 07:02 AMPZZA+2.34%NRGV-6.14%
Cathie Wood Loads Up On Amazon Stock After Record $26.4 Billion Prime Day, Bets Big On Palantir's AI Push — Keeps Dumping Alibababenzinga_article·Jun 29 at 10:04 PMABSI-5.69%PLTR-6.08%
Generate Biomedicines releases corporate presentation on programmable biology platform and clinical-stage pipelinePUBT·Jun 29 at 10:47 AMGENB-3.95%
Nvidia Owns This Under-the-Radar $20 Stock Poised to Disrupt a $1.8 Trillion MarketMotley Fool·Jun 27 at 07:10 AMGENB-3.95%NVDA+0.25%
